CREATE Medicines
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
$122MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies